$2.56
2.66% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US8006771062
Symbol
SGMO
Sector
Industry

Sangamo Therapeutics, Inc. Stock price

$2.56
+0.26 11.30% 1M
+2.16 542.25% 6M
+2.02 371.19% YTD
+2.02 376.72% 1Y
-5.68 68.93% 3Y
-5.80 69.38% 5Y
-12.33 82.81% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.07 2.66%
ISIN
US8006771062
Symbol
SGMO
Sector
Industry

Key metrics

Market capitalization $534.14m
Enterprise Value $522.67m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10.00
P/S ratio (TTM) P/S ratio 10.22
P/B ratio (TTM) P/B ratio 13.65
Revenue growth (TTM) Revenue growth -74.04%
Revenue (TTM) Revenue $52.29m
EBIT (operating result TTM) EBIT $-134.22m
Free Cash Flow (TTM) Free Cash Flow $-117.11m
Cash position $39.20m
EPS (TTM) EPS $-0.75
P/E forward negative
P/S forward 9.03
EV/Sales forward 8.84
Short interest 9.17%
Show more

Is Sangamo Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Sangamo Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Sangamo Therapeutics, Inc. forecast:

5x Buy
63%
3x Hold
38%

Analyst Opinions

8 Analysts have issued a Sangamo Therapeutics, Inc. forecast:

Buy
63%
Hold
38%

Financial data from Sangamo Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
52 52
74% 74%
100%
- Direct Costs 10 10
50% 50%
20%
42 42
77% 77%
80%
- Selling and Administrative Expenses 23 23
18% 18%
43%
- Research and Development Expense 143 143
42% 42%
274%
-124 -124
43% 43%
-237%
- Depreciation and Amortization 10 10
50% 50%
20%
EBIT (Operating Income) EBIT -134 -134
25% 25%
-257%
Net Profit -136 -136
45% 45%
-260%

In millions USD.

Don't miss a Thing! We will send you all news about Sangamo Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sangamo Therapeutics, Inc. Stock News

Positive
Seeking Alpha
9 days ago
Sangamo Therapeutics, Inc. received IND clearance to initiate a phase 1/2 study for ST-503 targeting idiopathic small fiber neuropathy, a type of chronic neuropathic pain condition. SGMO entered a deal with Astellas, allowing the use of its STAC-BBB capsid for the development of up to 5 neurological disorders; a $20 million upfront payment & $1.3 billion milestone payments. The global Neuropath...
Neutral
PRNewsWire
10 days ago
- Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales ...
Neutral
Business Wire
about one month ago
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ST-503 FOR THE TREATMENT OF IDIOPATHIC SMALL FIBER NEUROPATHY.
More Sangamo Therapeutics, Inc. News

Company Profile

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Head office United States
CEO Alexander Macrae
Employees 405
Founded 1995
Website www.sangamo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today